Risk Factors for Venous Thromboembolism in Patients With Diabetes Undergoing Joint Arthroplasty

Wei Deng  
Beijing Jishuitan Hospital and Fourth Medical College of Peking University Department of Radiology

Lili Huo  
Beijing Jishuitan Hospital  https://orcid.org/0000-0002-0815-4202

Qiang Yuan  
Beijing Jishuitan Hospital

Deyong Huang  
Beijing Jishuitan Hospital

Quan Li  
Beijing Jishuitan Hospital

Wei Tian (weitianjst@vip.163.com)  
Beijing Jishuitan Hospital

Research article

Keywords: Diabetes, Total knee arthroplasty, Total hip arthroplasty, Venous thromboembolism, Deep venous thrombosis

Posted Date: September 22nd, 2020

DOI: https://doi.org/10.21203/rs.3.rs-75562/v1

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License

Version of Record: A version of this preprint was published at BMC Musculoskeletal Disorders on July 6th, 2021. See the published version at https://doi.org/10.1186/s12891-021-04453-9.
Abstract

Background: Venous thromboembolism (VTE) is a significant complication after joint arthroplasty. Diabetes is related to a few changes in coagulation and fibrinolysis that may lead to thrombophilia. We aimed to investigate the incidence of and risk factors for VTEs in patients with diabetes undergoing total hip (THA) or total knee arthroplasty (TKA) in a single centre in China.

Methods: Patients with diabetes who underwent THA or TKA from January 2016 to December 2018 (n=400) at Beijing Jishuitan hospital were recruited in this study. Lower limb venous Doppler ultrasound was performed before and after surgery to confirm deep venous thrombosis (DVT). Computer tomography pulmonary angiography was done to confirm pulmonary embolism (PE) for those with new postoperative DVT and typical symptoms of PE. A multivariate logistic regression model was conducted to examine factors associated with the development of postoperative VTE.

Results: The overall incidence of postoperative VTE in patients with diabetes after THA or TKA was 46.8% (187 out of 400). Among the 187 VTE patients, 7.5% (14 out of 187) had proximal vein thrombosis and 92.5% (173 out of 187) had distal vein thrombosis. No PE occurred. Female patients and patients undergoing TKA had higher incidence of postoperative VTE. Patients who developed postoperative VTE were older, and had higher levels of preoperative D-Dimer level and Caprini score. Increased VTE risks were associated with high level of preoperative D-Dimer (OR=2.11, 95%CI=1.35-3.30) and TKA (OR=2.29, 95%CI=1.29-4.01). Postoperative initiation of concomitant mechanical prophylaxis and low molecular weight heparin (LMWH) was protective for postoperative VTE (OR=0.56, 95%CI=0.37-0.86).

Conclusions: VTE is common in patients with diabetes undergoing joint arthroplasty. Patients undergoing TKA or with a high level of preoperative D-Dimer are at a considerable risk of developing postoperative VTE. There may be a protective role of postoperative initiation of concomitant mechanical prophylaxis and LMWH for VTE.

Background

The aging population and rising incidence of arthritis have caused an increasing number of people undergoing joint arthroplasty, such as total hip arthroplasty (THA) or total knee arthroplasty (TKA). Over the last several decades, the global prevalence of diabetes has also increased significantly [1]. In China, there are currently more than 110 million people with diabetes and about 20% of people aged over 60 years old have diabetes[1]. Therefore, the number of people with diabetes selecting to undergo joint arthroplasty is proportionally increasing[2,3]. In 2008 a study from the U.S. including 751,340 THA or TKA patients revealed that 8.55% of patients have the comorbidity of diabetes and the risk of postoperative complications increased significantly for patients with diabetes[4].

Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially significant postoperative complication of arthroplasty surgery and
leads to an increase of mortality and morbidity, as well as an increase of the cost of care\textsuperscript{5}. The incidence of VTE following orthopedic surgery is highly variable due to heterogeneities of the studied populations, different treatment strategies and diagnostic measures, with published rates ranging from 1–2–60\% \textsuperscript{6–8}. Evidence shows that diabetes is related to a few changes in coagulation and fibrinolysis that may lead to thrombophilia\textsuperscript{9}. A longitudinal study investigating relationship between risk factors of coronary heart disease and VTE reported that diabetes and obesity both significantly increased the risk of incident VTE independently of age, race and sex\textsuperscript{10}. Those with diabetes at baseline had a 1.7-fold greater risk for VTE than those with normal fasting glucose levels\textsuperscript{10}. Additionally, patients with diabetes who subsequently developed VTE had a 74\% increase in the risk of recurrent DVT and 40\% increased risk of long-term major bleeding\textsuperscript{11}.

Although guidelines recommend routine VTE prophylaxis after arthroplasty surgery\textsuperscript{12}, the appropriate strategy for preventing VTE in high-risk arthroplasty surgery has been debated over several decades. The importance of VTE prophylaxis is more apparent for patients with diabetes undergoing THA or TKA. VTE treatment presents risks including heparin-induced thrombocytopenia and bleeding complications by itself. There are various risk assessment models (RAMs) for VTE in Western countries to stratify patients based on risk factors and help to deliver individualized VTE prophylaxis\textsuperscript{13–15}, but there is no clear data about VTE in Chinese patients with diabetes following THA or TKA. The aim of our study was to present the incidence of VTE among people with diabetes following THA or TKA and investigate its associated risk factors in current clinical practice. Such information is important for prediction of postoperative VTE and can be incorporated into the choice of appropriate thromboprophylaxis in this high-risk population.

\section*{Methods}

\subsection*{Data sources}

Patients who underwent THA or TKA at Beijing jishuitan hospital were enrolled in this study (n=400). From January 2016 to December 2018, 720 patients with diabetes had undergone THA or TKA at the Department of orthopedics. Patients who had THA or TKA due to infection, fracture, or arthrobrosis; patients who had history of malignancy or had received preoperative VTE prophylaxis; patients who had been diagnosed with VTE before surgery; patients without VTE-related images and tests of pre-operative D-Dimer were excluded from the study. The demographic and clinical information was obtained from electronic medical records.

\subsection*{Definition of VTE and diabetes}

Lower limb venous Doppler ultrasound was performed before and 3 to 5 days after surgery for screening of DVT. Computer tomography pulmonary angiography (CTPA) was done to confirm PE for those with new postoperative DVT and typical symptoms of PE. A VTE event was determined to have occurred if either a DVT or PE as defined previously occurred.
Patients were considered to have prevalent diabetes when this was documented in medical records or taking antiglycaemic agents for previously diagnosed diabetes.

Other demographic and clinical measures

The clinical status was evaluated when patients were admitted. Detailed anthropometric measurements were collected by trained nurses, adhering to standardized techniques. Standing height was measured to an accuracy of 0.1 cm and weight to an accuracy of 0.1 kilogram (kg). The body mass index (BMI) was calculated as weight in kilogram divided by the square of the height in meters. Blood pressure was measured twice on the right arm with an electronic sphygmomanometer (HEM-907; Omron Healthcare Company, Kyoto, Japan), in the sitting position, and was rounded to the nearest 1 mmHg. The average readings were used. Venous blood samples were obtained by nurses after an overnight fasting for 8-10h. Fasting levels of blood glucose were measured using an autoanalyzer (Hitachi 7600-110E/ Hitachi 7180E; Hitachi, Tokyo, Japan). Fasting levels of D-Dimer were measured by immunoturbidimetric assay using an automatic coagulation analyzer (Sysmex CS-5100, Sysmex Corporation, Japan). HbA1c concentration was measured by high-pressure liquid chromatography (D-10 Hemoglobin Testing System, Bio-Rad Laboratories, Inc., Schiltigheim, France).

Information about postoperative prophylaxis regimens were collected from electronic medical records. Mechanical prophylaxis was defined as either elastic stockings or foot pump. Written informed consent was obtained from all participants and this study was approved by the Ethics Committees of Beijing Jishuitan Hospital.

Statistical analysis

Data analysis was carried out using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Data were presented as median (25th, 75th Quartile), mean ± SD or n (%). Continuous variables were compared using either student's t test or Mann-Whitney U test. Categorical variables were compared using χ2 test or Fisher's exact test. Age (≥ 65 years versus < 65 years), gender (female versus male), smoking (smoking versus no smoking), preoperative comorbidities (hypertension, cerebrovascular disease and varicose veins of lower extremity versus none), BMI (≥ 28 kg/m² versus < 28 kg/m²), SBP (≥ 140 mmHg versus < 140 mmHg), DBP (≥ 90 mmHg versus < 90 mmHg), operative procedures (TKA versus THA), HbA1c (≥ 7.5% versus < 7.5%), preoperative D-Dimer (> 0.55 mg/L FEU versus ≤ 0.55 mg/L FEU) and postoperative prophylaxis regimens (mechanical prophylaxis versus concomitant mechanical prophylaxis and LMWH) were treated as independent variables, which were previously shown to be risk factors for VTE. A multivariable logistic regression analysis was performed to determine the independent risk factors for VTE. All analyses were two-tailed and P<0.05 was considered to be statistically significant.

Results

The detailed approach for participants' selection is shown in Fig. 1. A total of 400 patients with diabetes who underwent THA or TKA between January 2012 and December 2018 (n = 400) at Beijing Jishuitan
hospital were included in this study, 24.3% of whom were males. The mean age of these patients was 64.9 years. The overall incidence of postoperative VTE among patients with diabetes was 46.8% (187 of 400). Among 187 VTE patients, 7.5% (14 out of 187) had proximal vein thrombosis (popliteal vein or above) and 92.5% had distal vein thrombosis. No PE occurred. The incidence of VTE in patients who received THA was 32.3% (30 out of 97) with 3.3% of proximal vein thrombosis (1 out of 30), while the incidence of VTE after TKA was 51.1% (157 out of 307) with 8.3% of proximal vein thrombosis (13 out of 157).

Demographic and clinical characteristics of patients by VTE status are presented in Table 1. There were more females who developed VTE among this population. The mean surgery age of patients who developed VTE was significantly older than those without VTE (66.0 versus 64.1 years, P = 0.012). Furthermore, the preoperative D-Dimer in VTE patients was higher than in those without VTE (0.46 versus 0.40 mg/L FEU, P = 0.007). There was no difference in terms of prevalence of smoking, hypertension, cerebrovascular disease or varicose veins, BMI, SBP, DBP, preoperative fasting glucose, HbA1c and Caprini score between patients with and without VTE. Among this population, 55.5% of patients were given mechanical prophylaxis after THA or TKA for venous thromboembolism prophylaxis, while 45.5% of patients were given concomitant mechanical prophylaxis and low molecular weight heparin (LMWH). VTE incidence in patients who were given concomitant mechanical prophylaxis and LMWH after THA or TKA was significantly lower than in those who were given mechanical prophylaxis alone.
Table 1
Demographic and clinical characteristics of patients with diabetes undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA)

|                      | Total | VTE (+) | VTE (-) | Z value/t value/ $\chi^2$ value | P value |
|----------------------|-------|---------|---------|---------------------------------|---------|
| Gender (M/F)         | 97/303| 34/153  | 63/150  | 7.040                           | 0.010   |
| Age (years)          | 64.9 ± 7.7 | 66.0 ± 6.7 | 64.1 ± 8.3 | -2.513                          | 0.012   |
| Smoke, % (n)         | 16.5 (66) | 13.9 (26) | 18.8 (40) | 1.718                           | 0.225   |
| Alcohol drink, % (n) | 11.5 (46) | 11.2 (21) | 11.7 (25) | 0.025                           | 1.000   |
| Hypertension, % (n)  | 64.8 (259) | 64.7 (121) | 64.8 (138) | 0.000                           | 1.000   |
| Cerebrovascular disease, % (n) | 14.0 (56) | 15.0 (28) | 13.1 (28) | 0.276                           | 0.665   |
| BMI (kg/m$^2$)       | 26.9 ± 3.4 | 27.1 ± 3.5 | 26.7 ± 3.4 | -1.225                          | 0.221   |
| SBP (mmHg)           | 144 (131, 157) | 144 (133, 157) | 143 (130, 157) | -1.001                          | 0.317   |
| DBP (mmHg)           | 80 (73, 88) | 80 (72, 88) | 80 (73, 88) | -0.351                          | 0.725   |
| Preoperative fasting glucose (mmol/L) | 7.7 ± 2.2 | 7.8 ± 2.3 | 7.7 ± 2.1 | 0.104                           | 0.917   |
| HbA1c (%)            | 7.5 ± 1.5 | 7.6 ± 1.6 | 7.5 ± 1.4 | 0.189                           | 0.835   |
| Preoperative D-Dimer (mg/L FEU) | 0.43 (0.27, 0.83) | 0.46 (0.28, 1.14) | 0.40 (0.27, 0.66) | -2.696                          | 0.007   |
| Varicose veins, % (n) | 8.3 (33) | 8.0 (15) | 8.5 (18) | 0.024                           | 1.000   |
| Operative procedures |        |         |         |                                 |         |
| THA, % (n)           | 23.3 (93) | 32.3 (30) | 67.7 (63) | 10.222                          | 0.001   |
| TKA, % (n)           | 76.8 (307) | 51.1 (157) | 48.9 (150) |                                 |         |
| Caprini score        | 7.2 ± 0.7 | 7.2 ± 0.8 | 7.1 ± 0.8 | -0.827                          | 0.409   |

Table 2
Postoperative prophylaxis regimens of patients with diabetes undergoing total joint arthroplasty

|                      | Total | VTE (+) | VTE (-) | Z value/t value/ $\chi^2$ value | P value |
|----------------------|-------|---------|---------|---------------------------------|---------|
| Mechanical prophylaxis, % (n) | 55.5 (222) | 29.5 (118) | 26.0 (104) | 8.216                           | 0.005   |
| Mechanical prophylaxis + Low molecular weight heparin, % (n) | 44.5 (178) | 17.3 (69) | 27.2 (109) |                                 |         |
Table 3 summarises the results of the multivariable logistic regression analysis for postoperative VTE. We found that TKA was associated with 2.3-fold higher risk of VTE as compared to THA. Preoperative D-Dimer $>0.55$ (mg/L FEU) was associated with 2.1-fold higher risk of VTE as compared to preoperative D-Dimer $\leq 0.55$ (mg/L FEU). Mechanical prophylaxis and LMWH combined reduced the risk of VTE by 44% as compared with mechanical prophylaxis alone.

| Risk factors                                      | OR     | 95% CI for OR | P value |
|--------------------------------------------------|--------|---------------|---------|
| Age ($\geq 65$ years versus $<65$ years)          | 0.904  | 0.585–1.399   | 0.652   |
| Gender (female versus male)                       | 1.541  | 0.862–2.755   | 0.144   |
| Smoking (yes versus no)                           | 1.234  | 0.633–2.405   | 0.537   |
| Varicose veins (yes versus no)                    | 0.769  | 0.367–1.729   | 0.565   |
| Hypertension (yes versus no)                      | 0.828  | 0.518–1.326   | 0.432   |
| Cerebrovascular disease (yes versus no)           | 1.136  | 0.616–2.094   | 0.683   |
| BMI ($\geq 28$ kg/m$^2$ versus $<28$ kg/m$^2$)     | 0.834  | 0.536–1.300   | 0.423   |
| SBP ($\geq 140$ mmHg versus $<140$ mmHg)          | 1.143  | 0.720–1.812   | 0.571   |
| DBP ($\geq 90$ mmHg versus $<90$ mmHg)            | 0.976  | 0.561–1.699   | 0.932   |
| Operative procedures (TKA versus THA)             | 2.285  | 1.287–4.058   | 0.005   |
| HbA$_1$c ($\geq 7.5\%$ versus $<7.5\%$)          | 1.232  | 0.766–1.747   | 0.273   |
| Preoperative D-Dimer ($>0.55$ mg/L FEU versus $\leq 0.55$ mg/L FEU) | 2.109  | 1.348–3.300   | 0.001   |
| Postoperative prophylaxis regimens (mechanical prophylaxis versus concomitant mechanical prophylaxis and LMWH) | 0.559  | 0.365–0.855   | 0.007   |

**Discussion**
The overall incidence of postoperative VTE was 46.8% in patients with diabetes undergoing THA or TKA in this single center study and no PEs were confirmed. The majority of postoperative DVT identified in this study was distal vein thrombosis, which represented over 90% of all lower limb DVT. Patients with diabetes undergoing joint arthroplasty remain at high risk for developing postoperative VTE. Since guidelines for VTE prophylaxis were published, thromboprophylaxis with multiple strategies were routinely applied on most patients after arthroplasty surgery. This study is one of very few studies that investigate the incidence of and risk factors for VTE among patients with diabetes following joint arthroplasty under the real-world clinical practice, which may help to guide orthopaedic surgeons in their choice of VTE prophylaxis. We found that the VTE incidence for those undergoing TKA was 51.1%, which was higher than those undergoing THA. TKA was associated with 2.3-fold higher risk of postoperative VTE as compared with THA. This is consistent with other studies\textsuperscript{16,17}. It is possibly due to more extensive damage to soft-tissue and bone during TKA, which leads to the local release of tissue factors, thus initiating the coagulation cascade and also destruction of vascular anatomy\textsuperscript{18}.

D-dimer is a degradation product of cross-linked fibrin, and therefore a biomarker of coagulation activation and fibrinolysis. Plasma D-dimer level is often measured in order to screen VTE. A low D-dimer level may be useful for excluding acute thrombosis in clinical settings. However, there is a paucity of studies with respect to D-dimer as a risk factor for incident VTE. Our study suggests that high level of preoperative D-Dimer was an independent risk factor for postoperative VTE. Using a sample of the general US population, Cushman et al. found that higher baseline D-dimer level was correlated with increased risk of subsequent VTE\textsuperscript{19}. Another two case-control studies showed that patients with a history of VTE were more likely to have elevated D-dimer level than controls\textsuperscript{20,21}. A potential explanation proposed for the association between D-dimer and VTE is that D-dimer may be a marker for other factors associated with the pathophysiology of VTE. Evidence indicates that D-dimer is higher in the presence of genetic risk factors (eg. prothrombin 20210A, factor V Leiden, or elevated factor VIII:c) for VTE\textsuperscript{22}. However, these genetic mutations are rare in Asian populations\textsuperscript{23}. In addition, some possible risk factors for VTE such as age, smoking and inflammatory status are also reported to be associated with higher D-dimer\textsuperscript{24–26}. Therefore, measurement of baseline D-dimer may provide comprehensive clinical information than assessment of some specific thrombosis risk factors, such as genes or obesity.

Given that thromboprophylaxis has become the standard of care for patients undergoing THA or TKA, early mobilization combined with mechanical compressive device is highly recommended and has been the primary method of VTE prophylaxis in our center since 2012. In our study, all patients used mechanical prophylaxis for VTE after surgery and less than half of patients used LMWH. Concomitant use of mechanical prophylaxis and LMWH decreased the risk of VTE by 43% as compared with mechanical prophylaxis alone. A meta analysis including 14 trials showed that LMWH decreased asymptomatic DVT by 50% (combined risk ratio [RR], 0.50; 95% CI, 0.43–0.59) for major orthopedic surgery without significant increase in bleeding rates, which is similar with our result\textsuperscript{12}. However, it is necessary to measure the bleeding risk versus thrombotic risk before commencing pharmacological prophylaxis especially for situations where the patients’ personal bleeding risks are high.
There are various risk assessment models (RAMs) for VTE in Western countries, among which Caprini RAM is often applied to orthopedics inpatients. THA or TKA would give a score of 5 if assessed using the Caprini RAM. This places all patients in the high-risk category. In our study, no significant difference was found about Caprini score between patients with and without VTE. Therefore, Caprini RAM is highly sensitive but poorly specific for patients undergoing THA or TKA, which might not facilitate managing diverse patients with personalized VTE prophylactic strategies. Further studies need to be carried out to develop a specific VTE risk assessment model that serves this high risk population.

This study has several limitations. First, this study was carried out in only one large center, which limits its external validity in other population. Second, VTE in our study is defined as all venous thromboembolism including distal deep vein thrombosis, proximal vein thrombosis and PE. Whether distal deep vein thrombosis requires anticoagulant therapy is currently a debated issue due to its uncertain clinical significance. However, some investigators reported that therapeutic anticoagulation was associated with a significant reduction in the risk of extension to proximal DVT or PE among patients with distal deep vein thrombosis\(^{27,28}\). Current American College of Chest Physicians guidelines recommends therapeutic anticoagulation for distal deep vein thrombosis under the presence of the risk factors, such as active cancer, history of VTE or inpatient status\(^{12}\). As patients enrolled in our study could all be classified at high risk of developing VTE based on Caprini RAM, it might be reasonable to include distal deep vein thrombosis in the analysis. Lastly, lack of investigation of other risk factors such as anesthesia type, perioperative red blood cell transfusion and plasma homocysteine was also a limitation of this study.

**Conclusions**

VTE is common in patients with diabetes following joint arthroplasty. Patients undergoing TKA or with a high level of preoperative D-Dimer are at an increasing risk of VTE. There may be a protective role of postoperative initiation of concomitant mechanical prophylaxis and low molecular weight heparin for VTE.

**Declarations**

**Ethics approval and consent to participate**

Written informed consent was obtained from all participants and this study was approved by the Ethics Committees of Beijing Jishuitian Hospital.

**Consent for publication**

Not applicable.

**Availability of data and materials**
The datasets during and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by Beijing Municipal Science & Technology Commission (No. Z161100000116091).

**Authors' contributions**

WD and WT designed the study. QY, DYH and QL were involved in data collection. LH analyzed the data and wrote the first draft of the manuscript. WD, QY, DYH, QL and WT reviewed/edited the manuscript. WD, QY, DYH and QL were involved in laboratory analyses and quality control. All authors contributed to the interpretation of the results and revision of the manuscript for important intellectual content and approved the final version of the manuscript. WT is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Acknowledgments**

We are grateful to the research participants for their participation in this study. We are also grateful for the research team who contributed to the data collection and laboratory measurement.

**References**

1. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. *The New England journal of medicine*. Mar 25 2010;362(12):1090-1101.

2. Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. *The Journal of bone and joint surgery. American volume*. Feb 1 2012;94(3):201-207.

3. Cram P, Lu X, Kates SL, Singh JA, Li Y, Wolf BR. Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. *Jama*. Sep 26 2012;308(12):1227-1236.

4. Bolognesi MP, Marchant MH, Jr, Viens NA, Cook C, Pietrobon R, Vail TP. The impact of diabetes on perioperative patient outcomes after total hip and total knee arthroplasty in the United States. *The Journal of arthroplasty*. Sep 2008;23(6 Suppl 1):92-98.

5. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. *Journal of medical economics*. 2011;14(1):65-74.
6. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* Jun 2008;133(6 Suppl):381S-453S.

7. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. *The Journal of bone and joint surgery. British volume.* Mar 2006;88(3):386-391.

8. Pannucci CJ, Laird S, Dimick JB, Campbell DA, Henke PK. A validated risk model to predict 90-day VTE events in postsurgical patients. *Chest.* Mar 1 2014;145(3):567-573.

9. Jones EW, Mitchell JR. Venous thrombosis in diabetes mellitus. *Diabetologia.* Dec 1983;25(6):502-505.

10. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. *Archives of internal medicine.* May 27 2002;162(10):1182-1189.

11. Piazza G, Goldhaber SZ, Kroll A, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with diabetes mellitus. *The American journal of medicine.* Jul 2012;125(7):709-716.

12. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* Feb 2012;141(2 Suppl):e278S-e325S.

13. Samama MM, Combe S, Conard J, Horellou MH. Risk assessment models for thromboprophylaxis of medical patients. *Thrombosis research.* Feb 2012;129(2):127-132.

14. Rogers SO, Jr., Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. *Journal of the American College of Surgeons.* Jun 2007;204(6):1211-1221.

15. Obi AT, Pannucci CJ, Nackashi A, et al. Validation of the Caprini Venous Thromboembolism Risk Assessment Model in Critically Ill Surgical Patients. *JAMA surgery.* Oct 2015;150(10):941-948.

16. Markovic-Denic L, Zivkovic K, Lesic A, Bumbasirevic V, Dubljanin-Raspopovic E, Bumbasirevic M. Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study. *International orthopaedics.* Jun 2012;36(6):1299-1305.

17. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA, Jr., Global Orthopaedic Registry I. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. *Current medical research and opinion.* Jan 2008;24(1):87-97.

18. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. *Journal of thrombosis and thrombolysis.* Nov 2009;28(4):458-464.

19. Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. *Blood.* Feb 15 2003;101(4):1243-1248.
20. Andreescu AC, Cushman M, Rosendaal FR. D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. *Thrombosis and haemostasis*. Jan 2002;87(1):47-51.

21. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. *Thrombosis and haemostasis*. Apr 2000;83(4):530-535.

22. Ariens RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. *Lancet*. Feb 23 2002;359(9307):667-671.

23. Huang SS, Liu Y, Jing ZC, Wang XJ, Mao YM. Common genetic risk factors of venous thromboembolism in Western and Asian populations. *Genetics and molecular research : GMR*. Mar 4 2016;15(1):15017644.

24. Riva N, Camporese G, Iotti M, et al. Age-adjusted D-dimer to rule out deep vein thrombosis: findings from the PALLADIO algorithm. *Journal of thrombosis and haemostasis : JTH*. Feb 2018;16(2):271-278.

25. Lee AJ, Fowkes GR, Lowe GD, Rumley A. Determinants of fibrin D-dimer in the Edinburgh Artery Study. *Arteriosclerosis, thrombosis, and vascular biology*. Aug 1995;15(8):1094-1097.

26. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. *Arteriosclerosis, thrombosis, and vascular biology*. Mar 1999;19(3):493-498.

27. Utter GH, Dhillon TS, Salcedo ES, et al. Therapeutic Anticoagulation for Isolated Calf Deep Vein Thrombosis. *JAMA surgery*. Sep 21 2016;151(9):e161770.

28. De Martino RR, Wallaert JB, Rossi AP, Zbehlik AJ, Suckow B, Walsh DB. A meta-analysis of anticoagulation for calf deep venous thrombosis. *Journal of vascular surgery*. Jul 2012;56(1):228-237 e221; discussion 236-227.

**Figures**
Patients with diabetes undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) from January 2016 to December 2018 at the Department of orthopedics of Beijing Jishuitan Hospital.

Excluded
Patients who had THA or TKA due to infection, fracture, or arthrofibrosis, n=12
Patients who had history of malignancy or had received preoperative VTE prophylaxis, n=4
Patients who had been confirmed with VTE before surgery, n=58

Patients with diabetes undergoing THA or TKA for analysis, n=646

Excluded
Missing data of VTE-related image, n=59
Missing data of D-Dimer, n=187

Patients with diabetes undergoing THA or TKA for final analysis, n=400

Figure 1
Detailed approach for the selection of participant